SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from BioCardia, Inc. (BCDA) (CIK 0000925741) (BCDA) — Aug 1, 2019

BioCardia, Inc. (BCDA) (CIK 0000925741)
Date: Aug. 1, 2019 · CIK: 0000925741 · Accession: 0001437749-19-015089

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-230779

Date
July 31, 2019
Author
Clifford A. Teller
Form
CORRESP
Company
BioCardia, Inc. (BCDA) (CIK 0000925741)

Letter

Re:

bcda20190731b_corresp.htm

July 31, 2019

Securities and Exchange Commission

100 F. Street, NE

Washington, D.C. 20549

BioCardia, Inc.

Registration Statement on Form S-1

File No. 333-230779

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:30 p.m., Washington D.C. time, on Thursday, August 1, 2019, or as soon thereafter as practicable.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

(i)

Date of preliminary prospectus: July 23, 2019.

(ii)

Dates of distribution: July 23, 2019 through the date hereof.

(iii)

Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 12.

(iv)

Number of prospectuses so distributed: 540.

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

[Signature Page Follows]

MAXIM GROUP LLC

By: /s/ Clifford A. Teller

Name: Clifford A. Teller

Title: Executive Managing Director

Head of Investment Banking

Show Raw Text
CORRESP
1
filename1.htm

	bcda20190731b_corresp.htm

July 31, 2019

Securities and Exchange Commission

100 F. Street, NE

Washington, D.C. 20549

			Re:

			BioCardia, Inc.

			Registration Statement on Form S-1

			File No. 333-230779

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:30 p.m., Washington D.C. time, on Thursday, August 1, 2019, or as soon thereafter as practicable.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

			(i)

			Date of preliminary prospectus: July 23, 2019.

			(ii)

			Dates of distribution: July 23, 2019 through the date hereof.

			(iii)

			Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 12.

			(iv)

			Number of prospectuses so distributed: 540.

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

[Signature Page Follows]

MAXIM GROUP LLC

By:  /s/ Clifford A. Teller

Name: Clifford A. Teller

Title: Executive Managing Director

Head of Investment Banking